Safety and Preliminary Efficacy of FAB117-HC in Patients With Acute Traumatic Spinal Cord Injury
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The main objective of the study is the evaluation of the safety and tolerability of FAB117-HC
(a medicinal product containing human allogeneic adipose derived adult mesenchymal stem cells
expanded and pulsed with H2O2, HC016 cells) administered at a single-time point to patients
with acute thoracic traumatic spinal cord injury (SCI). The study will also include initial
exploration of potential clinical efficacy. Dose levels of 20 million and 40 million cells
will be administered.